# IZABRIGHT-Lung01 (NCT07100080)

> Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07100080
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Iza-bren; Carboplatin; Cisplatin; Pemetrexed
- Enrollment: 500
- Primary outcome: Recommended Phase 3 Dose (RP3D) of BMS-986507
- Primary outcome: Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=izabright-lung01-nct07100080

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07100080", "email": "<work email>"}; the inbox owner confirms by the emailed link.